Introgen Therapeutics Inc. said that preliminary data of a Phase III trial showed that Advexin, an investigational therapy that targets the abnormal p53 tumor suppressor function, which is associated with cancer initiation, progression and treatment resistance, significantly increased the survival of patients with head and neck cancer. (BioWorld Today) Read More
